X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Orchid Chemicals with ALEMBIC PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA LTD vs ALEMBIC PHARMA - Comparison Results

ORCHID PHARMA LTD    Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ORCHID PHARMA LTD ALEMBIC PHARMA ORCHID PHARMA LTD/
ALEMBIC PHARMA
 
P/E (TTM) x -0.1 20.3 - View Chart
P/BV x 0.1 4.8 2.6% View Chart
Dividend Yield % 0.0 0.7 -  

Financials

 ORCHID PHARMA LTD   ALEMBIC PHARMA
EQUITY SHARE DATA
    ORCHID PHARMA LTD
Sep-13
ALEMBIC PHARMA
Mar-18
ORCHID PHARMA LTD/
ALEMBIC PHARMA
5-Yr Chart
Click to enlarge
High Rs194645 30.1%   
Low Rs35470 7.4%   
Sales per share (Unadj.) Rs276.5166.1 166.5%  
Earnings per share (Unadj.) Rs-79.221.9 -361.7%  
Cash flow per share (Unadj.) Rs-43.527.5 -158.0%  
Dividends per share (Unadj.) Rs04.00 0.0%  
Dividend yield (eoy) %00.7 0.0%  
Book value per share (Unadj.) Rs53.9117.8 45.8%  
Shares outstanding (eoy) m70.45188.52 37.4%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x0.43.4 12.3%   
Avg P/E ratio x-1.425.5 -5.7%  
P/CF ratio (eoy) x-2.620.3 -13.0%  
Price / Book Value ratio x2.14.7 44.8%  
Dividend payout %018.3 0.0%   
Avg Mkt Cap Rs m8,067105,090 7.7%   
No. of employees `0002.8NA-   
Total wages/salary Rs m2,5276,228 40.6%   
Avg. sales/employee Rs Th6,956.1NM-  
Avg. wages/employee Rs Th902.5NM-  
Avg. net profit/employee Rs Th-1,993.0NM-  
INCOME DATA
Net Sales Rs m19,47731,308 62.2%  
Other income Rs m40770 579.2%   
Total revenues Rs m19,88431,378 63.4%   
Gross profit Rs m1,1036,431 17.1%  
Depreciation Rs m2,5191,055 238.9%   
Interest Rs m5,22734 15,372.9%   
Profit before tax Rs m-6,2365,413 -115.2%   
Minority Interest Rs m200-   
Prior Period Items Rs m0-81 0.0%   
Extraordinary Inc (Exp) Rs m5110-   
Tax Rs m-1251,204 -10.4%   
Profit after tax Rs m-5,5804,128 -135.2%  
Gross profit margin %5.720.5 27.6%  
Effective tax rate %2.022.2 9.0%   
Net profit margin %-28.713.2 -217.3%  
BALANCE SHEET DATA
Current assets Rs m11,01418,247 60.4%   
Current liabilities Rs m32,06011,235 285.4%   
Net working cap to sales %-108.122.4 -482.4%  
Current ratio x0.31.6 21.2%  
Inventory Days Days9586 110.9%  
Debtors Days Days3461 54.7%  
Net fixed assets Rs m29,44020,035 146.9%   
Share capital Rs m705377 186.9%   
"Free" reserves Rs m2,04321,824 9.4%   
Net worth Rs m3,80022,201 17.1%   
Long term debt Rs m9,0185,000 180.4%   
Total assets Rs m46,51039,411 118.0%  
Interest coverage x-0.2160.2 -0.1%   
Debt to equity ratio x2.40.2 1,053.8%  
Sales to assets ratio x0.40.8 52.7%   
Return on assets %-0.810.6 -7.2%  
Return on equity %-146.918.6 -789.8%  
Return on capital %-3.719.7 -18.9%  
Exports to sales %37.946.4 81.6%   
Imports to sales %22.610.5 215.4%   
Exports (fob) Rs m7,37814,535 50.8%   
Imports (cif) Rs m4,4063,288 134.0%   
Fx inflow Rs m7,51314,722 51.0%   
Fx outflow Rs m5,6497,026 80.4%   
Net fx Rs m1,8657,696 24.2%   
CASH FLOW
From Operations Rs m1,6823,124 53.8%  
From Investments Rs m-9,860-8,844 111.5%  
From Financial Activity Rs m6,6445,026 132.2%  
Net Cashflow Rs m-1,535-693 221.4%  

Share Holding

Indian Promoters % 32.3 74.1 43.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.6 2.9 158.6%  
FIIs % 3.3 9.1 36.3%  
ADR/GDR % 4.6 0.0 -  
Free float % 55.3 13.9 397.8%  
Shareholders   84,811 49,328 171.9%  
Pledged promoter(s) holding % 54.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ORCHID PHARMA LTD With:   TORRENT PHARMA  ALKEM LABORATORIES  AJANTA PHARMA  SANOFI INDIA  DR. DATSONS LABS  

Compare ORCHID PHARMA LTD With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Macroeconomic Cues Guide the Markets This Week(Podcast)

Global markets remained in pressure this week. Pound fell sharply as risk of chaotic Brexit rose.

Related Views on News

ALEMBIC PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 61.0% (Quarterly Result Update)

Oct 23, 2018 | Updated on Oct 23, 2018

For the quarter ended September 2018, ALEMBIC PHARMA has posted a net profit of Rs 2 bn (up 61.0% YoY). Sales on the other hand came in at Rs 11 bn (up 42.8% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ORCHID PHARMA LTD Announces Quarterly Results (4QFY18); Net Profit Up 50.8% (Quarterly Result Update)

Aug 24, 2018 | Updated on Aug 24, 2018

For the quarter ended March 2018, ORCHID PHARMA LTD has posted a net profit of Rs 924 m (up 50.8% YoY). Sales on the other hand came in at Rs 2 bn (down 24.0% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

Does it Make Sense to Invest in Offshore Funds?(Outside View)

Nov 6, 2018

Many investors prefer to invest in offshore funds because of the rupee depreciation and on-going downtrend in the markets, but it is to be invested only when there is no option available to invest in India.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA LTD SHARE PRICE


Nov 16, 2018 (Close)

TRACK ORCHID PHARMA LTD

  • Track your investment in ORCHID PHARMA LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ORCHID PHARMA LTD

ORCHID PHARMA LTD - TTK HEALTHCARE COMPARISON

COMPARE ORCHID PHARMA LTD WITH

MARKET STATS